EU schizophrenia guidance highlights unmet needs
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's new guidelines on developing schizophrenia treatments now include recommendations on R&D that targets the condition's traditionally overlooked negative and cognitive symptoms. The guidelines are encouraging because they highlight areas of unmet need, but developmental challenges mean they will not "translate into the launch of marketed products in the mid-term", said Charlotte Mackey, a lead analyst at Datamonitor.